ARAnna A. Ruleva

Anna A. Ruleva

*This is an algorithmically generated author record based on publicly available information.

Anna A. Ruleva has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Results of a clinical study of the influenza tetravalent inactivated subunit adjuvant vaccine Grippol Quadrivalent in children aged 6 months to 5 years (inclusive)

    by Viktor V. Romanenko, Leyla S. Namazova-Baranova, Alina A. Kotova, Kamilla E. Efendieva, Anna A. Ruleva, Ekaterina A. Khait, Olga A. Perminova, Tatiana E. Pak, Svetlana G. Lazareva, Liubov V. Aleshina, et al.

    The article presents the results of a clinical investigation on the administration of the Grippol Quadrivalent vaccine (influenza tetravalent inactivated subunit adjuvant vaccine) in children from 6 months to 5 years old. The vaccine has demonstrated no less effectiveness in comparison with the Grippol plus vaccine (influenza trivalent inactivated polymer-subunit vaccine).comparable results were obtained for all evaluated indicators of immunological efficacy against matching strains of the influenza virus, while for additional strain B (Yamagata line) there was a statistically significant difference in the increase in the immune response in the Grippol Quadrivalent group. The results of the assessment of the reactogenicity and frequency of systemic adverse events indicated a favorable and comparable safety profile of the vaccines Grippol Quadrivalent and Grippol plus in children from 6 months to 5 years old. The data obtained allowed us to conclude that the immunological efficacy of the Grippol Quadrivalent vaccine is no less when compared to the Grippol plus vaccine, as well as a comparable safety and reactogenicity profile. According to the results of the clinical investigation, on 08/04/2023, the Ministry of Health of the Russian Federation amended the “Instructions for the medical use of the drug”: Grippol Quadrivalent is indicated for children from the age of 6 months.

  • Open Access

    Vaccination against Measles in Patients with Oncological Disease

    by S. M. Kharit, I. V. Fridman, A. A. Ruleva

    Relevance. Growing distrust of vaccines around the world, a decrease in vaccination rates have led to an increase in the incidence of measles and a rise in the vulnerability of people with immunodeficiency status. The aim. To study the efficacy and safety of measles vaccination in children with oncohematological diseases. Materials & methods. The study involved 107 children: 74 of them with a history of acute lymphoblastic leukemia and 33 with solid tumors. All children had a history of receiving standardized polychemotherapy. In all the subjects, the vaccination history was studied, the titers of specific antibodies to measles were determined. Children with non-protective levels of antibodies (53 children) were subsequently vaccinated against measles. Results and discussions. Of the 107 children examined, before cancer, 99 (92.5%) were vaccinated against measles, of which 68 (68.7%) patients were only vaccinated, and 31 (31.3%) had vaccination and revaccination. Protective titers of antibodies against measles were preserved in 51 people (51.5%), and 48 (48.5%) were seronegative. When assessing immunogenicity on days 14, 45 after the introduction of the vaccine, it turned out that by day 14, 27 out of 53 children (50.9%) developed measles antibodies, and by day 45, 33 out of 53 children (62.3%), the rest of the children did not developed a protective level of antibodies, including 3 of 6 revaccinated. Conclusion. Thus, children with malignant diseases, regardless of the number of previous vaccinations and the duration of the end of therapy, become unprotected or have low titers of antibodies to measles in 83.8%, and immunization after treatment is effective in 62.3% of cases.

  • Open Access

    Influence of alpha-glutamil-tryptophan on the background and induced activity of factors of adaptive immunity for prevention

    by A. A. Ruleva, A. A. Krasnov, S. V. Petlenko, V. A. Zaplutanov, V. A. Apryatina

    Background. During the ongoing COVID-19 pandemic and in the season of rising incidence of other respiratory infections, it is relevant to use preventive measures of non-specific prophylaxis. Synthetic peptides are widely considered as a tool. The representative of this group is the synthetic analogue of thymus regulatory peptides Thymogen, which has been used in Russia for more than 20 years in the treatment of acute and chronic infection diseases.The aim of the study. To evaluate the effect of Thymogen, a dosed nasal spray, on induced parameters of the immune system during prophylactic use in healthy volunteers.Materials and methods. Twenty healthy volunteers received Thymogen nasal dosed spray (JSC “Cytomed”, Russia) at a dose of 25 μg twice a day for 10 days. A comparative assessment of immunological parameters was carried out in dynamics: before the start of therapy, on days 6 and 11 of taking the drug and 14 days after the end of the course. Clinical observation was carried out from day 1 to day 11, registration of adverse events – the entire period of the study for 24 days. The first day was considered the day the drug was started.Results. In the course of the work, according to the data of immunological examination, a statistically significant increase in the virus-induced production of interferon alpha (INF-α) by a culture of peripheral blood cells was revealed. The growth rate was recorded on day 11 of taking Thymogen and persisted for 14 days after the end of the course. Significant differences in the dynamics of bactericidal and phagocytic activity of neutrophils, serum α- and γ-interferon were not obtained.Conclusion. The use of Thymogen spray at a dose of 25 μg for 10 days was safe and contributed to a significant induction of interferon-alpha in response to exposure to a viral pathogen, which allows us to recommend the drug for prophylactic use during the period of rising incidence of acute respiratory diseases.

  • Open Access

    Preservation of Antibodies to Vaccine-Controlled Infections in Children WITH Oncological Diseases

    by S. M. Kharit, Yu. E. Konstantinova, O. V. Goleva, A. A. Ruleva, K. K. Tikhomirova, O. V. Iozefovich, I. V. Fridman

    Relevance. Cancer therapy forms a temporary immunosuppressive state, which determines an increase in the frequency and severity of infectious diseases. Vaccination is a highly effective and safe way to protect against infection, but people with immunodeficiency have risks of inefficiency and complications. To substantiate the need for immunoprophylaxis in cancer patients after therapy, it is important to understand the preservation of their specific response after previous vaccinations.The aim of the study was to assess the safety of antibodies to vaccine–controlled infections in children with oncological diseases after therapyMaterials and methods. The safety of antibodies to vaccine-controlled infections was studied in 3 groups: 1 -in patients with oncological (n=62); 2-in the group (n=43) withoutoncological diseases, but who received immunosuppressive (IST) and/or polychemotherapy (PCT) and/or hematopoietic stem cell transplantation (HSCT), and 3– in healthy children (n=31 – comparison group). The concentration of antibodies was determined by the ELISA method. The minimum protective level was considered to be the amount for measles ³0.18 IU/ml, rubella - ³25 IU/ml; hepatitis B - ³10 IU/ml; diphtheria – 0.03 IU/ml and higher. The coefficient of positivity, estimated as protective against mumps, was ³1.0.Results. It was found that from 41.7% to 93.7% of children with cancer lose post-vaccination immunity to the studied vaccine antigens. The number of children who retained the protective level of antibodies in groups 1 and 2 was significantly less than in the comparison group. There were no significant differences in the level of those protected from diphtheria and rubella. The maximum effect on the loss of antibodies is provided by the performed HSCT. For diphtheria and rubella antibodies, the differences are not pronounced. The possible connection of genetic breakdowns in 35 examined children with oncological diseases and the safety of antibodies was analyzed. It turned out that in the presence of chromosomal deletions, antibodies to measles were lost in 100% of cases and to diphtheria in 75%, which was different from other chromosomal abnormalities.Conclusion. The safety of antibodies in patients with a history of cancer is influenced by the presence of HSCT in therapy, the type of genetic breakdown, as well as the peculiarity of the vaccine antigen. Children with oncological diseases, as well as with non-oncological ones, but who have received HSCT therapy, should be vaccinated again against vaccine-controlled infections, despite the indication of the presence of vaccinations before therapy.


  • Open Access

    Establishing a Dialogue with a Patient on Vaccination (Scientific Review)

    by K. D. Ermolenko, S. M. Kharit, A. A. Ruleva, L. Yu. Drozdova

    Relevance. Vaccine prophylaxis is the most cost-effective and affordable means of controlling infectious diseases. At the same time, there is a great regional diversity in the number of people who refuse vaccination. In our country, according to several large studies, there is a relatively low adherence to vaccination compared to other European countries. It is common to have doubts and questions about immunization in adult patients or parents who vaccinate their children. A decrease in vaccination coverage of the population can lead to an increase in the incidence of infections preventable by immunization. At the same time, measures to promote vaccination used by preventive health care systems in various countries are insufficient. This increases the likelihood for doctors of various specialties to meet in their daily activities with patients' questions and concerns about vaccination.The purpose of this work was to highlight the practical aspects of building a dialogue with patients who have doubts about vaccination. Conclusions. Successful communication is based on the doctor's ability to build a confidential dialogue based on confidence in the decency and goodwill of all its participants. Based on the study, the following conclusions can be drawn. An alarming trend in recent years is the increasing number of patients who doubt the effectiveness of vaccination. For hesitant patients, the doctor is one of the most important sources of information about vaccines. The doctor's ability to clearly and confidently build a dialogue about vaccination helps to dispel the patient's doubts and is the most effective means of increasing adherence to immunization of the population.


  • Practical recommendations for the use of the alpha-glutamyl-tryptophan for respiratory diseases

    by A.A. Ruleva, V.A. Apryatina, Saint Petersburg Institute of Bioregulation and Gerontology, Yu.E. Konstantinova, K.K. Tihomirova

    Практические рекомендации по применению препарата альфа-глутамил-триптофан при респираторных заболеваниях

  • Immunological mechanisms of the drug Cytovir®-3 action as the basis of the prevention of acute respiratory viral infections and influenza

    by Pediatric Research and Clinical Center for Infectious Diseases under Federal Medical-Biological Agency, A.A. Ruleva, V.V. Popova, Saint-Petersburg State Pediatric Medical University of the Ministry of Health of the Russian Federation, A.V. Lyovina, Golikov Research Clinical Center of Toxicology of the Federal Medical-Biological Agency, A.A. Krasnov, S.V. Petlenko

    Иммунологические механизмы действия препарата Цитовир -3 в основе профилактики острых респираторных вирусных инфекций и гриппа


  • Open Access

    CLINICAL AND BACTERIOLOGICAL PECULIARITIES OF THE ACUTE OTITES MEDIA IN CHILDREN OF 0–5 YEARS OF AGE: PROVISIONAL DATA

    by Array Л. Перова, Array А. Рулева, S. S. Belanov, S. M. Kharit, S. V. Sidorenko

    Проведен анализ клинических особенностей и этиологической структуры отитов у 150 детей в возрасте от 0 до 5 лет включительно, госпитализированных с диагнозом «Острый средний отит», который был подтвержден отоскопически и при парацентезе. Жидкость, полученная при парацентезе, обследовалась в 128 случаях бактериологическим методом, в 129 — методом полимеразной цепной реакции. Этиологически расшифрован 121 случай болезни, пневмококк выделен у 93 детей (76,9%): как единственный возбудитель — в 31,4% и 45,5% — в сочетании с другими патогенами. Серотипирование пневмококков показало, что выделенные штаммы соответствуют зарегистрированным в России конъюгированным вакцинам против пневмококковой инфекции, что является обоснованием для проведения массовой вакцинации детей раннего возраста.